Early-Stop cancer trial tests novel drug duo for tough tumors
NCT ID NCT06682806
Summary
This study tested the safety and effectiveness of a new drug, PRT3789, combined with an existing immunotherapy (pembrolizumab) for people with advanced solid tumors that have a specific genetic change called a SMARCA4 mutation. The trial was designed for patients whose cancer had progressed on standard treatments or who couldn't receive them. The study was terminated early, enrolling only 6 participants instead of the planned 46-60.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Florida Cancer Specialists
West Palm Beach, Florida, 33401, United States
-
Hospital Universitario Fundacion Jimenez Diaz - Servicio de Oncologia
Madrid, 28040, Spain
-
IOB - Next Oncology - Hospital Quironsalud Barcelona
Barcelona, 08023, Spain
-
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey, 07601, United States
-
Karmanos Cancer Institute
Detroit, Michigan, 48201, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Barcelona - HM Nou Delfos
Barcelona, 08023, Spain
-
Tennessee Oncology, PLLC - Greco-Hainsworth Centers for Research
Nashville, Tennessee, 37203, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.